The biochemical aftermath of anti-amyloid immunotherapy

Table 4 ELISA quantification of TNF-α, Aβ40 and Aβ42

	GM	GM GDFA/GHCl-soluble Aβ			WM GDFA/GHCl-soluble Aβ			GM Tris-soluble Aββ
	TNF-α pg/mg total protein*	Aβ40 ng/mg total protein	Aβ42 ng/mg total protein**#	Total Aβ ng/mg total protein***	Aβ40 pg/mg total protein	Aβ42 pg/mg total protein	Total Aβ pg/mg total protein	Aβ40 pg/mg total protein	Aβ42 pg/mg total protein	Total Aβ pg/mg total protein
NDC
1	24	15	488	503	102	454	556	0	0	0
2	13	82	911	993	82	428	510	166	438	604
3	14	4	105	109	83	429	512	0	0	0
4	12	56	920	976	66	570	636	0	0	0
5	17	167	2168	2335	81	2596	2677	0	142	142
Mean	16	65	918	983	87	836	923	28	97	124
AD
6	11	5405	8152	13557	101	4122	4223	116	138	254
7	13	374	5910	6284	923	2379	3302	0	88	88
8	13	179	4773	4952	90	5156	5246	148	93	241
9	13	394	2664	3058	136	965	1101	254	66	320
10	15	96	5344	5440	91	1931	2022	0	35	35
11	18	7169	2847	10016	8940	13669	22609	151	0	151
Mean	14	2269	4948	7218	1714	4704	6417	112	70	182
Immunized AD
12	45	6347	58	6405	-	-	-	1260	0	1260
13	37	9925	1226	11151	-	-	-	13169	262	13431
14	32	252	31	283	-	-	-	0	0	0
15	32	1067	421	1488	-	-	-	629	26	655
16	43	8568	1570	10138	-	-	-	7556	142	7698
19	33	764	1565	2329	661	2141	2802	498	0	498
20	34	6315	7696	14011	7363	29669	37032	565	160	725
Mean	34	4748	1795	6544	4012	15905	19917	3382	84	3467
Immunized non-ADD
21 PSP	30	1	18	19	-	-	-	0	0	0
22 HS	13	3	333	336	158	1245	1403	0	0	0

* p < 0.0001; **p = 0.026; ***p = 0.007 unpaired, 2-tailed t-tests between AD and NDC cases. # p = 0.039 unpaired, 2-tailed t-tests between non-immunized and immunized AD individuals. NDC, non-demented control; AD, Alzheimer's disease; non-ADD, non-Alzheimer's disease dementias; TNF, tumor necrosis factor; GM, gray matter; WM, white matter; GHCl, guanidine hydrochloride, GDFA, glass-distilled formic acid; PSP, progressive supranuclear palsy; HS, hippocampal sclerosis.

ISSN: 1750-1326